2019-nCoV Vaccine mRNA-1273

mRNA vaccine against SARS-CoV-2, developed by Moderna.

Also Known As:

2019 nCoV Vaccine mRNA 1273; COVID 19 Vaccine Moderna; COVID-19 Vaccine, Moderna; CX 024414; CX024414; M 1273; M1273; Moderna COVID 19 Vaccine; Moderna COVID 19 Vaccine RNA; Moderna COVID 19 Vaccine, Bivalent; Moderna, COVID-19 Vaccine; TAK 919; TAK919; Vaccine, Moderna COVID-19; mRNA 1273; mRNA 1273.211; mRNA-1273, 2019-nCoV Vaccine; COVID-19 Vaccine Moderna; CX-024414; Elasomeran; M-1273; Moderna COVID-19 Vaccine; Moderna COVID-19 Vaccine RNA; Moderna COVID-19 Vaccine, Bivalent; Spikevax; TAK-919; mRNA-1273; mRNA-1273.211

Networked: 858 relevant articles (68 outcomes, 113 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Pajon, Rolando: 15 articles (11/2022 - 01/2021)
2.	Carfi, Andrea: 14 articles (02/2022 - 06/2020)
3.	Graham, Barney S: 14 articles (12/2021 - 06/2020)
4.	Edwards, Darin K: 13 articles (03/2022 - 10/2020)
5.	El Sahly, Hana M: 11 articles (11/2022 - 01/2021)
6.	Leav, Brett: 10 articles (11/2022 - 01/2021)
7.	Zhou, Honghong: 10 articles (11/2022 - 01/2021)
8.	Wu, Kai: 9 articles (02/2022 - 10/2020)
9.	Suthar, Mehul S: 9 articles (01/2022 - 02/2021)
10.	Corbett, Kizzmekia S: 9 articles (12/2021 - 06/2020)

Related Diseases

1.	COVID-19 02/01/2022 - "Phase 3 trials found mRNA-1273 was highly effective in preventing COVID-19. " 12/15/2021 - "Two doses of mRNA-1273 were highly effective against all SARS-CoV-2 variants, especially against hospital admission with covid-19. " 01/01/2023 - "Four mRNA-1273 doses provided significant protection against COVID-19 outcomes compared with 3 doses, consistent in various subgroups of demographic and clinical characteristics, although rVE varied and waned over time." 01/01/2022 - "Conclusion: CC genotype carriers of the GNB3 c.825C>T polymorphism have an increased T-cell immune response to SARS-CoV-2, which may indicate better T-cell-mediated protection against COVID-19 after vaccination with mRNA-1273." 01/01/2022 - "mRNA-1273 is effective in preventing SARS-CoV-2 infection in preschool children (6 months-6 years old). "
2.	Infections 05/01/2022 - "We conducted a test-negative case-control study to assess the durability of protection against symptomatic infection after vaccination with mRNA-1273. " 02/09/2022 - "Thus, in mice, boosting with mRNA-1273 or mRNA-1273.529 enhances protection against B.1.1.529 infection with limited differences in efficacy measured." 01/01/2022 - "Here, in exploratory analyses, we assessed the impact of mRNA-1273 vaccination in the ongoing COVE trial (number NCT04470427) on SARS-CoV-2 copy number and shedding, burden of disease and infection, and viral variants. " 01/01/2022 - "The scope was restricted to mRNA-1273 vaccinees and the Elecsys assay, the sample size was small, data on Delta and Omicron infections were lacking, and the analysis did not address a prespecified objective of the trial. " 10/06/2023 - "mRNA-1273 full vaccination plus mRNA-1273 booster showed the highest anti-infection effectiveness (47.59%) (95% CI, 46.72-48.45) in the overall cohort. "
3.	Myocarditis (Carditis) 01/01/2023 - "During the study period, 3017 myocarditis/myopericarditis cases among 252 million mRNA-1273 recipients who received at least 1 dose were reported to the Moderna global safety database. " 08/01/2022 - "A previous study reported that myocarditis after the mRNA-1273 vaccination was more prevalent in young men; however, no patients under 18 years old with myocarditis diagnosed by cardiovascular magnetic resonance (CMR) findings after mRNA-1273 vaccination have been reported in Japan. " 01/01/2023 - "Myocarditis/myopericarditis rates were not higher than expected for the overall population of mRNA-1273 recipients but were higher than expected in males aged 18-24 years, with most cases occurring 7 days after dose 2." 01/01/2023 - "Analysis of Myocarditis Among 252 Million mRNA-1273 Recipients Worldwide." 11/15/2022 - "The rate of myocarditis following mRNA-1273 receipt is highest among younger men (age 18-39 years) and does not seem to be present at older ages. "
4.	Breakthrough Infections 01/01/2023 - "Of 5516 BNT162b2 and 4322 mRNA-1273 recipients, 446 and 329 had a breakthrough infection, respectively. " 01/01/2023 - "mRNA-1273 recipients had a lower risk of breakthrough infection compared to BNT162b2 recipients (aHR 0.66, 95% CI: 0.50, 0.86). " 12/01/2022 - "SARS-CoV-2 Breakthrough Infection after mRNA-1273 Booster among CoronaVac-Vaccinated Healthcare Workers." 01/14/2022 - "Adjusted for demographic characteristics, clinical comorbidities, time of vaccination, and time of testing, the odds of experiencing a symptomatic breakthrough infection were lower after full vaccination with mRNA-1273 than with BNT162b2 (odds ratio: 0.60; 95% CI: 0.55-0.67). " 01/01/2022 - "Although we found both mRNA vaccines were effective, Moderna/mRNA-1273 had a lower incidence rate of breakthrough infections. "
5.	Asymptomatic Infections 11/04/2021 - "The efficacy in preventing severe disease was 98.2% (95% CI, 92.8 to 99.6), with 2 cases in the mRNA-1273 group and 106 in the placebo group, and the efficacy in preventing asymptomatic infection starting 14 days after the second injection was 63.0% (95% CI, 56.6 to 68.5), with 214 cases in the mRNA-1273 group and 498 in the placebo group. " 11/04/2021 - "The mRNA-1273 vaccine continued to be efficacious in preventing Covid-19 illness and severe disease at more than 5 months, with an acceptable safety profile, and protection against asymptomatic infection was observed. " 01/01/2023 - "We aim to estimate the effectiveness of 2-dose and 3-dose mRNA vaccination (BNT162b2 and mRNA-1273) against general Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection (asymptomatic or symptomatic) caused by the omicron BA.1 variant. "

Related Drugs and Biologics

1.	Vaccines
2.	BNT162 Vaccine
3.	Messenger RNA (mRNA)
4.	COVID-19 Vaccines
5.	mRNA Vaccines
6.	Ad26COVS1
7.	2019-nCoV Vaccine mRNA-1273
8.	sinovac COVID-19 vaccine
9.	Immunoglobulin G (IgG)
10.	Neutralizing Antibodies

Related Therapies and Procedures

1.	Injections
2.	Renal Replacement Therapy (Therapies, Renal Replacement)
3.	Artificial Respiration (Mechanical Ventilation)
4.	Immunotherapy
5.	Drug Therapy (Chemotherapy)